DRAFT General Regulation 202/94 of the *Pharmacy Act*
Clause by Clause Comparison of Proposed Amendments

Existing Clause	Proposed New Clause	Rationale
VII.3 (CONTROLLED ACTS)		
31. In this Part, “adapt” means to change a patient’s prescription respecting, (a) the dose of the prescribed drug, (b) the dosage form of the prescribed drug, (c) the directions for use of the prescribed drug, or 16 (d) the route of administration for taking the prescribed drug, but does not include therapeutic substitution; “Part A pharmacist” means a member who holds a certificate of registration as a pharmacist and who is listed in Part A of the register; “prescriber” means a person who is authorized under the laws of a province or territory of Canada to give a prescription within the scope of his or her practice of a health profession; “prescription” means a direction from a prescriber directing the dispensing of a drug or mixture of drugs for a specific patient; “renew” means to provide a patient with a prescription that repeats a prescription previously provided to that patient; “therapeutic substitution” means the substitution of a drug that contains chemically different active ingredients that are considered to be therapeutically equivalent.	**31.** In this Part, “adapt” means to change a patient’s prescription respecting, (a) the dose of the prescribed drug, (b) the dosage form of the prescribed drug, (c) the directions for use of the prescribed drug, or 16 (d) the route of administration for taking the prescribed drug, but does not include therapeutic substitution; “Part A pharmacist” means a member who holds a certificate of registration as a pharmacist and who is listed in Part A of the register; “point of care test” means a diagnostic test performed on a patient sample at the site of patient care; “prescriber” means a person who is authorized under the laws of a province or territory of Canada to give a prescription within the scope of his or her practice of a health profession; “prescription” means a direction from a prescriber directing the dispensing of a drug or mixture of drugs for a specific patient; “renew” means to provide a patient with a prescription that repeats a prescription previously provided to that patient; “therapeutic substitution” means the substitution of a drug that contains chemically different active ingredients that are considered to be therapeutically equivalent.	Adding a definition for “point of care test”.
34. (1) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) who meets all the requirements in subsection (3) is authorized to perform the following acts: 1. Administering a substance specified in Schedule 1 by injection to a patient. 2. Administering a substance specified in Schedule 2 by inhalation to a patient.	34. (1) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) who meets all the requirements in subsection (3) is authorized to perform the following acts: 1. Administering a substance specified in Schedule 1 by injection to a patient through a route other than direct intravenous, intravenous push, intravenous bolus, intrathecal, intraarticular, intracardiac, intraspinal, intraocular, and intracavernous. 2. Administering a substance specified in Schedule 2 by inhalation to a patient.	The current regulation restricts administration of substances by injection and inhalation for the purposes of patient education and demonstration, which inherently limits the route of administration. The new regulation removes the restriction on the purpose of administration, resulting in the need to specify which routes of administration are beyond the scope of practice of a pharmacist.

Existing Clause	Proposed New Clause	Rationale
[…] (3) A member may only perform an act provided for in subsection (1) if he or she complies with the following: 1. The member may only perform the act for the purpose of patient education and demonstration, and before performing the act, i. must explain that purpose to the patient or his or her authorized agent, and ii. must receive an informed consent from the patient or his or her authorized agent. 2. The member shall ensure that he or she only performs the act in an environment that is clean, safe, private and comfortable for the patient. 3. The member shall ensure that appropriate infection control procedures are in place. 4. The member must possess sufficient knowledge, skill and judgment respecting the substance to be administered, and sufficient understanding of the condition of the patient, to be able to administer the substance safely. 5. The member must consider whether administering a substance by injection or inhalation to the patient is appropriate, given the known risks and benefits to the patient and the safeguards and resources available to safely manage the outcome after administration and any other relevant circumstances. 6. The member must maintain a patient record that includes, i. the name and address of the patient, ii. the name and address of the member, iii. the date the act was performed, iv. the name, strength (where applicable) and quantity of the substance that the member administered to the patient, v. the circumstances relating to the administration of the substance to the patient and any adverse reaction experienced by the patient, and vi. confirmation that an informed consent was given by the patient or his or her authorized agent.	[…] (3) A member may only perform an act provided for in subsection (1) if he or she complies with the following: 1. The member ~~may only perform the act for the purpose of patient education and demonstration, and before performing the act,~~ ~~i. must explain that purpose to the patient or his or her authorized agent, and~~ ~~ii.~~ must receive an informed consent from the patient or his or her authorized agent before performing the act. 2. The member shall ensure that he or she only performs the act in an environment that is clean, safe, private and comfortable for the patient. 3. The member shall ensure that appropriate infection control procedures are in place. 4. The member must possess sufficient knowledge, skill and judgment respecting the substance to be administered, and sufficient understanding of the condition of the patient, to be able to administer the substance safely. 5. The member must consider whether administering a substance by injection or inhalation to the patient is appropriate, given the known risks and benefits to the patient and the safeguards and resources available to safely manage the outcome after administration and any other relevant circumstances. 6. The member must maintain a patient record that includes, i. the name and address of the patient, ii. the name and address of the member, iii. the date the act was performed, iv. the name, strength (where applicable) and quantity of the substance that the member administered to the patient, v. the circumstances relating to the administration of the substance to the patient and any adverse reaction experienced by the patient, and vi. confirmation that an informed consent was given by the patient or his or her authorized agent. 7. Where the act is performed for a purpose other than patient education and demonstration, the member must notify the	The restrictions removed in section 34(3)1. allow for the administration of substances by injection and inhalation beyond the purposes of patient education and demonstration (i.e. for therapeutic purposes). Numbering is adjusted as necessary. Communication of services that are provided for patient care or therapeutic purposes are necessary to support continuity and co-ordination of care among the health team.

Existing Clause	Proposed New Clause	Rationale
	patient's primary care provider (if any) within a reasonable time that the member performed the act and provide details respecting the act.	
34. (4) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) is authorized to administer influenza vaccine by injection to a patient who is five years of age or older, if the member, (a) administers the vaccine in accordance with Ontario's Universal Influenza Immunization Program as described on the Ministry's website; (b) receives an informed consent from the patient or his or her authorized agent; and (c) meets all the requirements in paragraphs 2 to 6 of subsection (3). (5) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) is authorized to administer a vaccine from one of the vaccines specified in Schedule 3 by injection to a patient who is five years of age or older, if the member, (a) receives an informed consent from the patient or his or her authorized agent; (b) meets all the requirements in paragraphs 2 to 6 of subsection (3); and (c) notifies the patient's primary care provider (if any) within a reasonable time that the member administered a vaccine to the patient and provides details respecting the administration.	34. (4) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) is authorized to administer influenza vaccine by injection to a patient who is ~~five~~ two years of age or older, if the member, (a) administers the vaccine in accordance with Ontario's Universal Influenza Immunization Program as described on the Ministry's website; and ~~(b) receives an informed consent from the patient or his or her authorized agent; and~~ (~~c~~b) meets all the requirements ~~2~~ 1 to 6 of subsection (3). (5) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) is authorized to administer a vaccine from one of the vaccines specified in Schedule 3 by injection to a patient who is five years of age or older, if the member, (a) ~~receives an informed consent from the patient or his or her authorized agent; (b~~) meets all the requirements in paragraphs ~~2~~1 to 6 of subsection (3); and (~~c~~b) notifies the patient's primary care provider (if any) within a reasonable time that the member administered a vaccine to the patient and provides details respecting the administration.	The change in age allows for the administration of the influenza vaccination by injection to a patient who is two years of age or older. Numbering is adjusted as necessary. Removal of the requirement to provide informed consent in subsection (4)a and (5)a is to remove repetition in the drafting. The requirement for informed consent is referenced in paragraph 1 of subsection (3). As noted above, the deletion reduces repetition and the requirement remains in paragraph 1 of subsection (3).
36. (1) For the purposes of paragraph 4 of subsection 4 (1) of the Act, a member referred to in subsection (3) who complies with the other provisions of this section is authorized to perform the following acts: 1. Adapting a patient's prescription. 2. Renewing a patient's prescription for the purpose of continuity of care. […]	36. (1) For the purposes of paragraph 4 of subsection 4 (1) of the Act, a member referred to in subsection (3) who complies with the other provisions of this section is authorized to perform the following acts: 1. Adapting a patient's prescription. 2. Renewing a patient's prescription for the purpose of continuity of care. […]	

Existing Clause	Proposed New Clause	Rationale
(4) A member may only perform an act provided for in subsection (1) if he or she complies with the following: […] 2. If the member is renewing a prescription, he or she must not prescribe a quantity of the drug that exceeds the lesser of, i. the quantity that was originally prescribed, including any refills that were authorized by the prescriber, and ii. a six months'supply.	(4) A member may only perform an act provided for in subsection (1) if he or she complies with the following: […] 2. If the member is renewing a prescription, he or she must not prescribe a quantity of the drug that exceeds the lesser of, i. the quantity that was originally prescribed, including any refills that were authorized by the prescriber, and ii. a ~~six~~ twelve months' supply.	Changing a "six months' supply" to a "twelve months' supply" allows pharmacists to renew prescriptions for up to 12 months, enabling greater access and continuity of care to patients, and potentially reducing some of the burden on the system, particularly for patients without access to a primay care physician (e.g. unnecessary visits to the emergency room department).
39. (1) For the purposes of paragraph 5 of subsection 4 (1) of the Act, a member referred to in subsection (2) who meets all the requirements in subsection (4) is authorized to perform the act of piercing a patient's dermis with a lancet-type device to obtain blood. (2) A member who is a Part A pharmacist, an intern, a registered pharmacy student or a pharmacy technician is authorized to perform the act provided for in subsection (1), subject to the terms, conditions and limitations imposed on his or her certificate of registration. (3) A pharmacy technician shall not perform the act provided for in subsection (1) unless, (a) a Part A pharmacist is physically present on the premises at the time when the pharmacy technician performs the act; and (b) the pharmacy technician is under the direction of a Part A pharmacist at the time when the pharmacy technician performs the act.	39. (1) For the purposes of paragraph 5 of subsection 4 (1) of the Act, and subject to subsection (3), a member referred to in subsection (2) who meets all the requirements in subsection (4) is authorized to perform the act of piercing a patient's dermis with a lancet-type device to obtain blood. (2) A member who is a Part A pharmacist, an intern, a registered pharmacy student or a pharmacy technician is authorized to perform the act provided for in subsection (1), subject to the terms, conditions and limitations imposed on his or her certificate of registration. (3) A pharmacy technician shall not perform the act provided for in subsection (1) unless, (a) a Part A pharmacist is physically present on the premises at the time when the pharmacy technician performs the act; ~~and~~ (b) the pharmacy technician is under the direction of a Part A pharmacist at the time when the pharmacy technician performs the act, and (c) where the act is performed to administer a point of care test, a Part A pharmacist interprets the results of the test and makes the professional decision arising from the results of the test.	The current regulation restricts the act of piercing the dermis to purposes related to patient education and self monitoring of a chronic disease. Removal of this restriction allows for members to perform the act of piercing the dermis for other purposes, such as point of care testing. This is an enabling change in the event that point of care testing is permitted in the future as a result of amendments to the Ministry's regulations under the Laboratory Speciman Collection and Centre Licensing Act. Numbering is adjusted as necessary. Consistent with the scope of practice of pharmacy technicians, this addition enables performamce of the act of piercing the dermis for additional purposes, but restricts pharmacy technicians from interpreting the results and making a therapeutic decision to act on the results of the test
(4) A member may only perform the act provided for in subsection (1) if he or she complies with the following: 1. The member may only perform the act for the purpose of demonstrating the appropriate use of lancet-type devices for the patient's self care and education or for the patient's self monitoring of his or her chronic disease, and before performing the act, i. shall explain that purpose to the patient or his or her authorized agent, and	(4) A member may only perform the act provided for in subsection (1) if he or she complies with the following: 1. ~~The member may only perform the act for the purpose of demonstrating the appropriate use of lancet-type devices for the patient's self care and education or for the patient's self monitoring of his or her chronic disease, and before performing the act,~~ i. ~~shall explain that purpose to the patient or his or her authorized agent, and ii. shall~~ The	As noted above, removal of the specific purpose for performing the act of piercing the dermis enables additional purposes such as point of care testing.

Existing Clause	Proposed New Clause	Rationale
ii. shall receive an informed consent from the patient or his or her authorized agent. 2. The member shall ensure that he or she only performs the act in an environment that is clean, safe, private and comfortable for the patient. 3. The member shall ensure that appropriate infection control procedures are in place. 4. The member must possess the knowledge, skill and judgment respecting the performance of the act and understand the condition of the patient, to perform it safely and effectively. 5. The member must consider whether performing the act on the patient is appropriate, given the known risks and benefits to the patient and the safeguards and resources available to safely manage the outcome and any other relevant circumstances. 6. The member must maintain a patient record that includes, i. the name and address of the patient and the member, ii. the date the act was performed, and iii. confirmation that an informed consent was given by the patient or his or her authorized agent.	member must receive an informed consent from the patient or his or her authorized agent before performing the act. 2. The member shall ensure that he or she only performs the act in an environment that is clean, safe, private and comfortable for the patient. 3. The member shall ensure that appropriate infection control procedures are in place. 4. The member must possess the knowledge, skill and judgment respecting the performance of the act and understand the condition of the patient, to perform it safely and effectively. 5. The member must consider whether performing the act on the patient is appropriate, given the known risks and benefits to the patient and the safeguards and resources available to safely manage the outcome and any other relevant circumstances. 6. The member must maintain a patient record that includes, i. the name and address of the patient ~~and the member,~~ , ii. the ~~date~~name and address of the member, iii. the date the act was performed, ~~and~~ ~~iii.~~ iv. the circumstances relating to the act and any adverse reaction experienced by the patient, v. where the member performed the act to administer a point of care test, the results of the test, vi. the professional decision arising from the results of the point of care test and the rationale for the decision, and vii. confirmation that an informed consent was given by the patient or his or her authorized agent. 7. Where the act is performed for a purpose other than patient education and demonstration, the member must notify the patient's primary care provider (if any) within a reasonable time that the member performed the act and provide details respecting the act.	Communication of services that are provided for patient care or therapeutic purposes are necessary to support continuity and co-ordination of care among the health team. These requirements are consistent with the other patient care documentation requirments in earlier sections of the regulation, and include additional requirements specific to point of care testing.

DRAFT General Regulation 202/94

Clause by Clause Comparison

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
Rationale for proposed changes:	Specific substances have been added or removed to this list based on their currency and in order to be comprehensive, inclusive and align with market availability. No restrictions on dose are currently proposed. Pharmacists must continue to adhere to the College's Guideline for Administering a Substance by Injection or Inhalation. Substances not listed in the Schedules to the regulations may only be administered in the context of a medical directive.	Drug categories have been added to correspond with their currency and in order to be comprehensive, to increase patient access to care and patient convenience (e.g. antipsychotic medications, local anesthetics). No restrictions on dose are currently proposed. Pharmacists must continue to adhere to the College's Guideline for Administering a Substance by Injection or Inhalation.
SCHEDULE 1 INJECTED SUBSTANCES (Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification) 1. 8:00 Anti-infective Agents	SCHEDULE 1 INJECTED SUBSTANCES (Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification) 1. 8:00 Anti-infective Agents i. 8:12 Antibacterials A. 8:12.02 Aminoglycosides 1. Amikacin 2. Gentamicin B. 8:12.06.04 First Generation Cephalosporins 1. Cefazolin	SCHEDULE 1 INJECTED SUBSTANCES (Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification) 1. 8:00 Anti-infective Agents i. 8:12 Antibacterials

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
	C. 8:12.06.12 Third Generation Cephalosporins 1. Cefotaxime 2. Ceftazidime 3. Ceftriaxone D. 8:12.06.16 Fourth Generation Cephalosporins 1. Cefepime E. 8:12.07.08 Carbapenems 1. Ertapenem F. 8:12.07.12 Cephamycins 1. Cefoxitin G. 8:12.16.04 Natural Penicillins 1. Penicillin G H. 8:12.16.08 Aminopenicillins 1. Ampicillin I. 8:12.16.12 Pencillinase-Resistant Penicillins 1. Cloxacillin J. 8: 12.28.20 Lincomycins 1. Clindamycin K. 8:12.28.28 Polymyxins 1. Colistin	
i. 8:18 Antivirals A. 8:18.08.04 HIV Entry and Fusion Inhibitors 1. Enfuvirtide B. 8:18.20 Interferons	ii. 8:18 Antivirals A. 8:18.08.04 HIV Entry and Fusion Inhibitors 1.Enfuvirtide B. 8:18.20 Interferons 1. Interferon Alfa-2b 2. Peginterferon alfa-2a	ii. 8:18 Antivirals.

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
1. Interferon Alfa-2b 2. Peginterferon alfa-2a 3. Peginterferon alfa-2b	~~3. Peginterferon alfa-2b~~ 3. Peginterferon Beta-1a	
2. 10:00 Antineoplastic Agents 1. Goserelin 2. Leuprolide 3. Methotrexate	2. 10:00 Antineoplastic Agents 1. Goserelin 2. Leuprolide 3. Methotrexate 4. Fulvestrant 5. Triptorelin acetate 6. Rituximab	2. 10:00 Antineoplastic Agents
3. 12:00 Autonomic Drugs	3.12:00 Autonomic Drugs i. 12:08.08 Antimuscarinic Antispasmodics 1. Atropine	3. 12:00 Autonomic Drugs i. 12:08.08 Antimuscarinic Antispasmodics
i. 12:12 Sympathomimetic (Adrenergic) Agents A. 12:12.12 Alpha- and Beta-Adrenergic Agonists 1. Scopolamine 2. Hyoscine 3. Glycopyrrolate 4. Epinephrine	ii. 12:12 Sympathomimetic (Adrenergic) Agents A.12:12.12 Alpha- and Beta-Adrenergic Agonists 1.Scopolamine 2.Hyoscine 3.Glycopyrrolate 4.Epinephrine	ii. 12:12 Sympathomimetic (Adrenergic) Agents
	iii. 12:16 Sympatholytic (Adrenergic Blocking) Agents 1. Dihydroergotamine	iii. 12:16 Sympatholytic (Adrenergic Blocking) Agents
4. 20:00 Blood Formation and Coagulation i. 20:04 Antianemia Drugs A. 20:04.04 Iron Preparations	4. 20:00 Blood Formation and Coagulation i. ~~20:04 Antianemia Drugs~~ ~~A.20:04.04 Iron Preparations~~	4. 20:00 Blood Formation and Coagulation ~~i. 20:04 Antianemia Drugs~~
1. Iron	1.~~Iron~~ i. 20:12 Coagulants and Anticoagulants	i. 20:12 Coagulants and Anticoagulants

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
ii. 20:12 Coagulants and Anticoagulants A. 20:12.04 Anticoagulants 1. Dalteparin 2. Danaparoid 3. Enoxaparin 4. Fondaparinux 5. Heparin 6. Nadroparin 7. Tinazaparin	A. 20:12.04 Anticoagulants 1. Dalteparin 2. Danaparoid 3. Enoxaparin 4. Fondaparinux 5. Heparin 6. Nadroparin 7. Tinazaparin	
iii. 20:16 Hematopoietic Agents 1. Ancestim 2. Darbepoetin alfa 3. Epoetin alfa 4. Filgrastim 5. Pegfilgrastim 6. Romiplostim	ii. 20:16 Hematopoietic Agents 1. Ancestim 2. Darbepoetin alfa 3. Epoetin alfa 4. Filgrastim 5. Pegfilgrastim 6. Romiplostim	ii. 20:16 Hematopoietic Agents
	iii. 20:28.92 Antihemorrhagic Agents, Miscellaneous 1. Emicizumab	iii. 20:28.92 Antihemorrhagic Agents, Miscellaneous
5. 28:00 Central Nervous System Agents i. 28:08 Analgesics and Antipyretics A. 28:08.08 Opiate Agonists 1. Codeine 2. Hydromorphone	5. 24:00 Cardiovascular Drugs i. 24:06.24 Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors 1. Alirocumab 2. Evolocumab 6. 28:00 Central Nervous System Agents i. 28:08 Analgesics and Antipyretics A.28:08.08 Opiate Agonists 1. Codeine 2. Hydromorphone 3. ~~Meperidine~~	5. 24:00 Cardiovascular Drugs i. 24:06.24 Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors 6. 28:00 Central Nervous System Agents i. 28:08 Analgesics and Antipyretics

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
3. Meperidine 4. Morphine B. 28:08.12 Opiate Partial Agonists 1. Nalbuphine 2. Pentazocine	3. Morphine B. 28:08.12 Opiate Partial Agonists 1. Nalbuphine 2. Pentazocine	
	ii. 28:10 Opiate Antagonists Naloxone	ii. 28:10 Opiate Antagonists
ii. 28:16 Psychotherapeutic Agents A. 28:16.08 Antipsychotics 1. Haloperidol 2. Methotrimeprazine	iii. 28:16 Psychotherapeutic Agents A. 28:16.08 Antipsychotics 1. Haloperidol 2. Methotrimeprazine 3. Aripiprazole 4. Flupentixol 5. Methotrimeprazine 6. Paliperidone 7. Risperidone 8. Zuclopenthixol 9. Fluphenazine 10. Olanzapine	iii. 28:16 Psychotherapeutic Agents
	iv. 28:24.08 Benzodiazepines 1.Lorazepam 2.Diazepam 3.Midazolam	iv. 28:24.08 Benzodiazepines
iii. 28:32 Antimigraine Agents	v. 28:32 Antimigraine Agents A. 28:32:12 Calcitonin-Gene-Related Peptide (CGRP) Antagonists 1. Erenumab	v. 28:32 Antimigraine Agents
A. 28:32.28 Selective Serotonin Agonists 1. Sumatriptan	B. 28:32.28 Selective Serotonin Agonists 1. Sumatriptan	
	vi. 28.36 Antiparkinsonian Agents	vi. 28.36 Antiparkinsonian Agents

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
	A. 28:36.20.08 Nonergot-derivative Dopamine Receptor Agonists 1.Apomorphine B. 28:36.08 Anticholinergic Agents 1.Benztropine	
	vii. 28:92 Miscellaneous Central Nervous System Agents 1. Inotersen	vii. 28:92 Miscellaneous Central Nervous System Agents
6. 40:00 Electrolytic, Caloric, and Water Balance i. 40:12 Replacement Preparations 1. Normal saline	7. 40:00 Electrolytic, Caloric, and Water Balance i.40:12 Replacement Preparations 1.Normal saline	7. 40:00 Electrolytic, Caloric, and Water Balance i. 40:12 Replacement Preparations
	8. 44:00 Enzymes 1. Asfotase Alfa	8. 44:00 Enzymes
7. 48:00 Respiratory Tract Agents i. 48:92 Respiratory Tract Agents, Miscellaneous 1. Omalizumab	9. 48:00 Respiratory Tract Agents i. 48:92 Respiratory Tract Agents, Miscellaneous 1.Omalizumab 2. Benralizumab	9. 48:00 Respiratory Tract Agents i. 48:92 Respiratory Tract Agents, Miscellaneous
8. 56:00 Gastrointestinal Drugs i. 56:22 Antiemetics A. 56:22.08 Antihistamines 1. Dimenhydrinate 2. Prochlorperazine ii. 56:32 Prokinetic Agents 1. Metoclopropamide iii. 56:92 GI Drugs, Miscellaneous 1. Certolizumab Pegol	10. 56:00 Gastrointestinal Drugs i. 56:22 Antiemetics A. 56:22.08 Antihistamines 1. Dimenhydrinate ~~2. Prochlorperazine~~ ii. 56:32 Prokinetic Agents 1. Metoclopropamide iii. 56:92 GI Drugs, Miscellaneous 1. Certolizumab Pegol 2. Methylnaltrexone	10. 56:00 Gastrointestinal Drugs i. 56:22 Antiemetics ii. 56:32 Prokinetic Agents iii. 56:92 GI Drugs, Miscellaneous
	11. 64:00 Heavy Metal Antagonists	

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
2. Methylnaltrexone 9. 64:00 Heavy Metal Antagonists 1. Deferoxamine 10. 68:00 Hormones and Synthetic Substitutes i. 68:18 Gonadotropins 1. Follitropin-alpha 2. Follitropin-beta 3. Gonadotropin-chorionic 4. Gonadotropin-chorionic-alfa 5. Gonadotropin-human 6. Lutropin-alfa 7. Menotropins 8. Urofollitropin ii. 68:20 Antidiabetic Agents 1. Exenatide 2. Insulins 3. Liraglutide	1. Deferoxamine 12. 68:00 Hormones and Synthetic Substitutes i. 68:04 Adrenals 1. Betamethasone 2. Tetracosactide 3. Hydrocortisone 4. Dexamethasone 5. Prednisolone 6. Methylprednisolone ii. 68:08 Androgens 1. Testosterone iii. 68:18 Gonadotropins 1. Follitropin-alpha 2. Follitropin-beta 3. Follitropin-delta 4. Gonadotropin-chorionic 5. Gonadotropin-chorionic-alfa 6. Gonadotropin-human 7. Lutropin-alfa 8. Menotropins 9. ~~Urofollitropin~~ iv. 68:20 Antidiabetic Agents 1.Exenatide 2.Insulins 3.Liraglutide 4. Dulaglutide	11. 64:00 Heavy Metal Antagonists 12. 68:00 Hormones and Synthetic Substitutes i. 68:04 Adrenals ii. 68:08 Androgens iii. 68:18 Gonadotropins iv. 68:20 Antidiabetic Agents

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
	5. Lixisenatide 6. Semaglutide	
iii. 68:22 Antihypoglycemic Agents A. 68:22:12 Glycogenolytic Agents 1. Glucagon	v. 68:22 Antihypoglycemic Agents A. 68:22:12 Glycogenolytic Agents 1. Glucagon	v. 68:22 Antihypoglycemic Agents
iv. 68:24 Parathyroid 1. Calcitonin Salmon 2. Teriparatide	vi. 68:24 Parathyroid 1. Calcitonin Salmon 2. Teriparatide	vi. 68:24 Parathyroid
v. 68:28 Pituitary 1. Desmopressin 2. Vasopressin	vii. 68:28 Pituitary 1. Desmopressin 2. Vasopressin	vii. 68:28 Pituitary
	viii. 68:29:04 Somatostatin Agonists 1. Pasireotide	viii. 68:29:04 Somatostatin Agonists
vi. 68:30 Somatotropin Agonists and Antagonists A. 68:30.04 Somatotropin Agonists 1. Somatropin	ix. 68:30 Somatotropin Agonists and Antagonists A. 68:30.04 Somatotropin Agonists 1. Somatropin 2. Tesamorelin	ix. 68:30 Somatotropin Agonists and Antagonists
B. 68:30.08 Somatotropin Antagonists 1. Pegvisomant	B. 68:30.08 Somatotropin Antagonists 1. Pegvisomant	
vii. 68:32 Progestins 1. Medroxyprogesterone	x. 68:32 Progestins 1. Medroxyprogesterone Progesterone	x. 68:32 Progestins
	xi. 68:36:04 Thyroid Agents Levothyroxine	xi. 68:36:04 Thyroid agents
	13. 72:00 Local Anesthetics 1. Lidocaine	13. 72:00 Local Anesthetics

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
	2. Prilocaine 3. Articaine 4. Bupivacaine 5. Mepivacaine	
	14. 84:92 Misc. Skin and Mucous Membrane Agents 1. Brodalumab 2. Dupilumab 3, Guselkumab 4. Ixekizumab 5. Risankizumab 6. Secukinumab	14. 84:92 Misc. Skin and Mucous Membrane Agents
11. 88:00 Vitamins i. 88:08 Vitamin B Complex 1. Cyanocobalamin 2. Folic Acid 3. Methylcobalamin 4. Pyridoxine 5. Thiamine ii. 88:12 Vitamin C 1. Ascorbic Acid iii. 88:24 Vitamin K Activity 1. Vitamin K	15. 88:00 Vitamins i. 88:08 Vitamin B Complex 1. Cyanocobalamin 2. Folic Acid ~~3.Methylcobalamin~~ 4. Pyridoxine 5. Thiamine ii. 88:12 Vitamin C 1. Ascorbic Acid iii. 88:24 Vitamin K Activity 1. Vitamin K	15. 88:00 Vitamins i. 88:08 Vitamin B Complex ii. 88:12 Vitamin C iii. 88:24 Vitamin K Activity
12. 92:00 Miscellaneous Therapeutic Agents i. 92:12 Antidotes	16. 92:00 Miscellaneous Therapeutic Agents ~~i. 92:12 Antidotes~~ 1. ~~Leucovorin~~ i. 92:20 Biologic Response Modifiers	16. 92:00 Miscellaneous Therapeutic Agents ~~i. 92:12 Antidotes~~ i. 92:20 Biologic Response Modifiers

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
1. Leucovorin ii. 92:20 Biologic Response Modifiers 1. Denosumab 2. Glatiramer 3. Interferon-Beta-1A 4. Interferon-Beta-1B 5. Natalizumab iii. 92:36 Disease-modifying Antirheumatic Drugs 1. Abatacept 2. Adalimumab 3. Anakinra 4. Etanercept 5. Gold Sodium Thiomalate 6. Golimumab 7. Ustekinumab iv. 92:40 Gonadotropin- releasing Hormone Antagonists 1. Cetrorelix 2. Ganirelix	1. Denosumab 2. Glatiramer 3. Interferon-Beta-1A 4. Interferon-Beta-1B ~~5. Natalizumab~~ ii. 92:32 Complement Inhibitors Icatibant Lanadelumab iii. 92:36 Disease-modifying Antirheumatic Drugs 1. Abatacept 2. Adalimumab 3. Anakinra 4. Etanercept ~~5. Gold Sodium Thiomalate~~ 6. Golimumab 7. Ustekinumab 8. Sarilumab 9. Tocilizumab iv. 92:40 Gonadotropin- releasing Hormone Antagonists 1. Cetrorelix 2. Ganirelix v. 92:44 Immunosuppressive Agents 1.Belimumab 2.Mepolizumab vi. 92:92 Other Miscellaneous Therapeutic Agents	ii. 92:32 Complement Inhibitiors iii. 92:36 Disease-modifying Antirheumatic Drugs iv. 92:40 Gonadotropin- releasing Hormone Antagonists v. 92:44 Immunosuppressive Agents vi. 92:92 Other Miscellaneous Therapeutic Agents

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
v. 92:92 Other Miscellaneous Therapeutic Agents 1. Octreotide 13. Miscellaneous 1. Sterile Water for Injection (Diluent)	1. Octreotide 2. Lanreotide 17. Miscellaneous 1. Sterile Water for Injection (Diluent)	17. Miscellaneous

DRAFT General Regulation 202/94

Clause by Clause Comparison

Existing Clause	Proposed New Clause (List)	Proposed New Clause (Categories)
SCHEDULE II INHALED SUBSTANCES		
Rationale for proposed changes:	Specific substances have been added or removed to this list based on their currency and in order to be comprehensive, inclusive and align with market availability. No restrictions on dose are currently proposed. Pharmacists must continue to adhere to the College's Guideline for Administering a Substance by Injection or Inhalation. Substances not listed in the Schedules to the regulations may only be administered in the context of a medical directive.	Drug categories have been added to correspond with their currency and in order to be comprehensive, to increase patient access to care and patient convenience. No restrictions on dose are currently proposed. Pharmacists must continue to adhere to the College's Guideline for Administering a Substance by Injection or Inhalation.

SCHEDULE 2 INHALED SUBSTANCES (Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification)	SCHEDULE 2 INHALED SUBSTANCES (Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification)	SCHEDULE 2 INHALED SUBSTANCES (Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification)
1. 8:00 Anti-infective Agents i. 8:18 Antivirals A. 8:18.28 Neuraminidase Inhibitors 1. Zanamivir ii. 8:12 Antibacterials A. 8:12.07.16 Monobactams 1. Tobramycin 2. Aztreonam	1.8:00 Anti-infective Agents i.8:18 Antivirals A.8:18.28 Neuraminidase Inhibitors 1. Zanamivir ii.8:12 Antibacterials A.8:12.07.16 Monobactams 1. Tobramycin 2. Aztreonam B. 8:12.18 Quinolones 1. Levofloxacin	1. 8:00 Anti-infective Agents i.8:18 Antivirals ii.8:12 Antibacterials
2. 12:00 Autonomic Drugs i. 12:08 Anticholinergic Agents A. 12:12.08 Antimuscarinics/Antispasmodics 1. Ipratropium 2. Tiotropium	2.12:00 Autonomic Drugs i.12:08 Anticholinergic Agents A. 12:08.08 Antimuscarinics/Antispasmodics 1. Ipratropium 2.Tiotropium 3. Umeclidinium 4. Aclidinium	2.12:00 Autonomic Drugs i.12:08 Anticholinergic Agents

ii. 12:12 Sympathomimetic (Adrenergic) Agents A. 12:12.08.12 Selective Beta2- Adrenergic Agonists 1. Fenoterol 2. Formoterol 3. Salbutamol 4. Salmeterol 5. Terbutaline	ii. 12:12 Sympathomimetic (Adrenergic) Agents A.12:12.08.12 Selective Beta2- Adrenergic Agonists ~~1. Fenoterol~~ 2. Formoterol 3. Salbutamol 4. Salmeterol 5. Terbutaline 6. Vilanterol 7. Indacaterol 8. Olodaterol	ii. 12:12 Sympathomimetic (Adrenergic) Agents
iii. 12:16 Sympatholytic (Adrenergic Blocking) Agents A. 12:16.04.04 Non-Selective alpha-Adrenergic Blocking Agents 1. Dihyroergotamine	iii. 12:16 Sympatholytic (Adrenergic Blocking) Agents A. 12:16.04.04 Non-Selective alpha-Adrenergic Blocking Agents 1.Dihyroergotamine	iii. 12:16 Sympatholytic (Adrenergic Blocking) Agents
iv. 12:92 Autonomic Drugs, Miscellaneous 1. Nicotine	iv.12:92 Autonomic Drugs, Miscellaneous 1. Nicotine	iv. 12:92 Autonomic Drugs, Miscellaneous
3. 28:00 Central Nervous System Agents i. 28:08 Analgesics and Antipyretics A. 28:08.12 Opiate Partial Agonists 1. Butorphanol	3.28:00 Central Nervous System Agents i.28:08 Analgesics and Antipyretics A.28:08.12 Opiate Partial Agonists 1.Butorphanol	3.28:00 Central Nervous System Agents i. 28:08 Analgesics and Antipyretics
ii. 28:32 Antimigraine Agents A. 28:32.28 Selective Serotonin Agonists	ii.28:32 Antimigraine Agents A. 28:32.28 Selective Serotonin Agonists	ii. 28:32 Antimigraine Agents

1. Sumatriptan 2. Zolmitriptan 4. 40:00 Electrolytic, Caloric, and Water Balance i. 40:12 Replacement Preparations 1. Sodium chloride 5. 48:00 Respiratory Tract Agents i. 48:24 Mucolytic Agents 1. Dornase alfa 6. 52:00 Eye, Ear, Nose and Throat (EENT) Preparations i. 52:02 Antiallergic Agents 1. Sodium Cromoglycate 2. Levocabastine ii. 52:08 Anti-inflammatory Agents A. 52:08.08 Corticosteroids 1. Beclomethasone 2. Budesonide 3. Ciclesonide 4. Flunisolide 5. Fluticasone 6. Mometasone 7. Triamcinolone	1. Sumatriptan 2. Zolmitriptan 4.40:00 Electrolytic, Caloric, and Water Balance i.40:12 Replacement Preparations 1. Sodium chloride 5.48:00 Respiratory Tract Agents i.48:12.08 Anticholinergic Agents 1. Glycopyrronium ii. 48:24 Mucolytic Agents 1.Dornase alfa 6. 52:00 Eye, Ear, Nose and Throat (EENT) Preparations i.52:02 Antiallergic Agents 1.Sodium Cromoglycate 2. Levocabastine ii. 52:08 Anti-inflammatory Agents A. 52:08.08 Corticosteroids 1. Beclomethasone 2. Budesonide 3. Ciclesonide 4. Flunisolide 5. Fluticasone 6. Mometasone	4. 40:00 Electrolytic, Caloric, and Water Balance i.40:12 Replacement Preparations 5.48:00 Respiratory Tract Agents i.48:12.08 Anticholinergic Agents ii. 48:24 Mucolytic Agents 6. 52:00 Eye, Ear, Nose and Throat (EENT) Preparations i.52:02 Antiallergic Agents ii.52:08 Anti-inflammatory Agents

iii. 52:32 Vasoconstrictors 1. Oxymetazoline 2. Phenylephrine 3. Xylometazoline 7. 68:00 Hormones and Synthetic Substitutes i. 68:18 Gonadotropins 1. Buserelin 2. Nafarelin ii.68:24 Parathyroid 1.Calcitonin Salmon iii.68:28 Pituitary 1. Desmopressin 2. Vasopressin 8. 92:00 Miscellaneous Therapeutic Agents i. 92:12 Antidotes 1. Acetylcysteine	7. Triamcinolone iii.52:32 Vasoconstrictors 1. Oxymetazoline 2. Phenylephrine 3. Xylometazoline 7.68:00 Hormones and Synthetic Substitutes i.68:18 Gonadotropins 1. Buserelin 2. Nafarelin ~~ii.68:24 Parathyroid~~ ~~1. Calcitonin Salmon~~ ii.68:28 Pituitary 1. Desmopressin 2. Vasopressin 8. 92:00 Miscellaneous Therapeutic Agents i. 92:12 Antidotes 1. Acetylcysteine .	iii.52:32 Vasoconstrictors 7.68:00 Hormones and Synthetic Substitutes i.68:18 Gonadotropins ~~ii.68:24 Parathyroid~~ ii.68:28 Pituitary 8. 92:00 Miscellaneous Therapeutic Agents i. 92:12 Antidotes